secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261797
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences reports Q3 net loss $80.9M; cash $390.9M; PEAK, APEX readouts in Nov/Dec 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities at $390.9M; pro forma cash $430M expected to fund into 2027.
- Net loss of $80.9M (Q3 2025) vs $70.6M (Q3 2024); R&D expenses $69.0M.
- Phase 3 PEAK (GIST) top-line results expected Nov 2025; APEX (AdvSM) in Dec 2025.
- NDA filing for NonAdvSM on track for year-end 2025; Breakthrough Therapy Designation granted for bezuclastinib.
- Raised $215.8M net from public offering and $39M from ATM since July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/0001193125-25-261797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer